Mayo Clinic | Strategic Alliance Partners

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Kathryn Ruddy, MD, associate professor of Oncology, Mayo Clinic, discusses the management of central nervous system (CNS) metastases in HER2-positive breast cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.

Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the evolution of treatment for patients with pancreatic cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.

Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the ReDOS study of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Ramesh K. Ramanathan, MD, discusses sequencing strategies and emerging therapeutic targets in pancreatic cancer.

Tanios Bekaii-Saab, MD, outlines clinical trials that have defined the current landscape of metastatic colorectal cancer and what research is underway.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Tanios Bekaii-Saab, MD, discusses neoadjuvant and adjuvant strategies in treating patients with early-stage pancreatic cancer.

Daniel Ahn, DO, discusses advances and challenges with targeted and immune-based therapies in the treatment of patients with gastric and gastroesophageal cancer.

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses emerging therapeutic targets in patients with pancreatic cancer.

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.